Today's early-phase psilocybin studies (cancer, smokers, AUD) yield only feasibility/safety data, no efficacy readouts, this year.

Current psilocybin studies focused on cancer patients, smokers, and people with alcohol problems are small and designed mainly to check whether the treatment is safe — not to prove it's effective. These are early-stage trials, meaning researchers are still figuring out doses and side effects. Solid proof that psilocybin actually treats these conditions is still years away.

These are Phase 1/2 designs. Small n, open-label features. Rigorous efficacy claims are years away. Rushing translation is my core concern.